Evidence map›Paper›PMID 36260016›Full record

ReviewNanoscale horizons2022

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases.

Seokhwan Chung, Chan Mi Lee, Miqin Zhang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanoscale horizons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Seokhwan ChungDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, USA. mzhang@uw.edu.
Chan Mi LeeDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, USA. mzhang@uw.edu.
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, USA. mzhang@uw.edu.ORCID 0000-0001-8974-1494
University of Washington · US

Funding

Iron oxide nanotheranostics for breast cancerR01EB026890 · NIBIB · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2018 to 2021
$1.9M
NIBIB NIH HHS R01 EB026890
6 · The paper itself

Abstract

The liver is a vital organ that functions to detoxify the body. Liver cancer and infectious diseases such as influenza and malaria can fatally compromise liver function. mRNA delivery is a relatively new means of therapeutic treatment which enables expression of tumor or pathogenic antigens, and elicits immune responses for therapeutic or prophylactic effect. Novel nanoparticles with unique biological properties serving as mRNA carriers have allowed mRNA-based therapeutics to become more clinically viable and relevant. In this review, we highlight recent progress in development of nanoparticle-based mRNA delivery systems for treatment of various liver diseases. First, we present developments in nanoparticle systems used to deliver mRNAs, with specific focus on enhanced cellular uptake and endosomal escape achieved through the use of these nanoparticles. To provide context for diseases that target the liver, we provide an overview of the function and structure of the liver, as well as the role of the immune system in the liver. Then, mRNA-based therapeutic approaches for addressing HCC are highlighted. We also discuss nanoparticle-based mRNA vaccines for treating hepatotropic infectious diseases. Finally, we present current challenges in the clinical translation of nanoparticle-based mRNA delivery systems and provide outlooks for their utilization in treating liver-related diseases.

Indexed as

Carcinoma, HepatocellularCommunicable DiseasesLiver NeoplasmsNanoparticlesHumansRNA, MessengerRNA, Messenger

Identifiers

PMID36260016
PMCPMC11144305
OpenAlexW4306833407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.